PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$110.20
as of September 23, 2026 -
YTD RETURNS8.34%
as of September 23, 2026 -
Total Net Assets$1.00B
as of September 23, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 2.45 | 8.50 | 11.15 | 29.87 | 13.65 | 10.41 | 8.78 | 10.31 |
| PPH (Market Price) | 2.43 | 8.57 | 11.13 | 29.92 | 13.65 | 10.41 | 8.79 | 10.39 |
| MVIS US Listed Pharmaceutical 25 Index | 2.46 | 8.50 | 10.94 | 29.69 | 13.30 | 10.05 | 8.53 | 10.12 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | 4.42 | 5.83 | 6.97 | 27.15 | 13.83 | 10.55 | 8.46 | 10.15 |
| PPH (Market Price) | 4.40 | 6.13 | 6.86 | 27.12 | 13.83 | 10.52 | 8.46 | 10.22 |
| MVIS US Listed Pharmaceutical 25 Index | 4.38 | 5.74 | 6.73 | 26.87 | 13.35 | 10.15 | 8.20 | 9.95 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 09/23/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
20.43 |
206,860,527 |
|
MRK |
Merck & Co Inc |
13.47 |
136,403,744 |
|
NVO |
Novo Nordisk A/S |
5.60 |
56,664,052 |
|
PFE |
Pfizer Inc |
5.06 |
51,239,159 |
|
BMY |
Bristol-Myers Squibb Co |
4.74 |
47,955,236 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.65 |
47,051,014 |
|
GSK |
Gsk Plc |
4.59 |
46,470,300 |
|
MCK |
Mckesson Corp |
4.43 |
44,892,293 |
|
COR |
Cencora Inc |
4.34 |
43,908,129 |
|
HLN |
Haleon Plc |
3.71 |
37,543,267 |
|
ABBV |
Abbvie Inc |
3.65 |
36,927,765 |
|
AZN |
Astrazeneca Plc |
3.59 |
36,377,184 |
|
NVS |
Novartis Ag |
3.58 |
36,283,589 |
|
JNJ |
Johnson & Johnson |
3.48 |
35,227,355 |
|
SNY |
Sanofi Sa/France |
3.36 |
33,983,104 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.78 |
28,176,872 |
|
ZTS |
Zoetis Inc |
2.52 |
25,469,385 |
|
VTRS |
Viatris Inc |
1.44 |
14,568,367 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.33 |
13,455,805 |
|
AXSM |
Axsome Therapeutics Inc |
0.76 |
7,727,941 |
|
CORT |
Corcept Therapeutics Inc |
0.75 |
7,582,001 |
|
ELAN |
Elanco Animal Health Inc |
0.50 |
5,037,173 |
|
DFTX |
Definium Therapeutics Inc |
0.48 |
4,850,374 |
|
OGN |
Organon & Co |
0.29 |
2,907,012 |
|
PRGO |
Perrigo Co Plc |
0.10 |
1,004,396 |
|
-USD CASH- |
-- |
0.12 |
1,242,229 |
|
-- |
Other/Cash |
0.27 |
2,690,172 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 08/31/2026
-
Sector
% of Net Assets -
Health Care
99.79 -
Other/Cash
0.21
Country Weightings (%) as at 08/31/2026
-
Country
% of Net Assets -
United States
63.70 -
United Kingdom
10.90 -
Switzerland
9.98 -
Denmark
4.91 -
France
4.03 -
Israel
3.15 -
Japan
3.12 -
Other/Cash
0.21
Fees
Distributions
as of 09/23/2026
Quarterly
1.85%
2.27%
1.97%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency